Skip to main content

Dr. Jonathan G. Stine, MD

Gastroenterology (Gastroenterology Physician)

  • Medicare participating

At a glance

In the NPI registry since
2009
Medicare patients seen, 2024
195

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2009Registered with an NPI (national billing number; not a license date)

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Gastroenterology Physician primary
    PA license MD461663 · VA license 0101247916

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Gastroenterology per capita by county →

Medicare patients and services

Medicare patients, 2024
195
Services billed
250
Patients’ average age
70
Most frequent Medicare services, 2023
ServiceTimesPatients
Measurement of liver stiffness6261
Established patient office or other outpatient visit, 40-54 minutes6157
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes2114
Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes1414

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 1 companies reported 10 payments worth $8,139 in total to this clinician.

By company
Madrigal Pharmaceuticals$8,139
By type
Consulting Fee$7,050
Food and Beverage$573
Travel and Lodging$516

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Apr 11, 2025Madrigal Pharmaceuticals
Apr 11, 2025
Consulting Fee
REZDIFFRA · LIVER DISEASE
$5,640
Mar 10, 2025Madrigal Pharmaceuticals
Mar 10, 2025
Consulting Fee
REZDIFFRA · LIVER DISEASE
$1,410
Apr 11, 2025Madrigal Pharmaceuticals
Apr 11, 2025
Travel and Lodging
REZDIFFRA · LIVER DISEASE · travel to PHILADELPHIA, PA · in-kind
$303
Apr 11, 2025Madrigal Pharmaceuticals
Apr 11, 2025
Travel and Lodging
REZDIFFRA · LIVER DISEASE · travel to PHILADELPHIA, PA
$148
Apr 12, 2025Madrigal Pharmaceuticals
Apr 12, 2025
Travel and Lodging
REZDIFFRA · LIVER DISEASE · travel to PHILADELPHIA, PA · in-kind
$65.30

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Pennsylvania →

Industry-funded research

Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $50,449 in research payments for these studies, mostly to the institutions running them.

  • A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
    Regeneron Pharmaceuticals, Inc. · Recruiting · NCT05519475
  • A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fib…
    AstraZeneca Pharmaceuticals LP
  • AZD2693, Cardiovascular, Renal and Metabolism
    AstraZeneca UK Limited
  • A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepati…
    Boehringer Ingelheim International GmbH
  • A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/…
    Boehringer Ingelheim International GmbH

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Gastroenterology clinicians in Hershey

Sources

NPI registry (CMS NPPES, November 2026; record last updated March 7, 2023), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1932333440. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.